Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Colorectal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm
Colorectal Neoplasm

Subtype

Colorectal Neoplasm

CI-CAN-00002404Explore in graph →

Non-malignant1,784 active trials21 approved drugs382 evidence items

NCIt: C2956
MeSH: D015179

Overview
Statistics
Survival
Genomics27
Variants & evidence382
Drugs79
Trials8604
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.
· PLoS One · 2014 · PMID 24594804 · validated civic_curation pubmed
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
· J Clin Oncol · 2017 · PMID 28486044 · validated civic_curation pubmed
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
· JAMA · 2010 · PMID 20978259 · validated civic_curation pubmed
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
· Clin Cancer Res · 2009 · PMID 19934290 · validated civic_curation pubmed
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
· Ann Oncol · 2012 · PMID 21926398 · validated civic_curation pubmed
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
· Cancer Sci · 2010 · PMID 19922504 · validated civic_curation pubmed
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
· Clin Cancer Res · 2015 · PMID 25520391 · validated

Showing 176–200 of 357 publications

← Previous
1
…
7
8
9
…
15
Next →

civic_curation

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

· Br J Cancer · 2015 · PMID 25989278 · validated civic_curation pubmed

The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.

· Int J Cancer · 2013 · PMID 23456958 · validated civic_curation pubmed

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.

· J Cancer Res Clin Oncol · 2013 · PMID 23435830 · validated civic_curation pubmed

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

· N Engl J Med · 2016 · PMID 26789870 · validated civic_curation pubmed

Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

· JAMA Oncol · 2016 · PMID 26867820 · validated civic_curation pubmed

KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.

· Med Oncol · 2013 · PMID 23828442 · validated civic_curation pubmed

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

· Eur J Cancer · 2016 · PMID 26812186 · validated civic_curation pubmed

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

· J Clin Oncol · 2015 · PMID 26460303 · validated civic_curation pubmed

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

· Lancet · 2012 · PMID 22608338 · validated civic_curation pubmed

Cetuximab for the treatment of colorectal cancer.

· N Engl J Med · 2007 · PMID 18003960 · validated civic_curation pubmed

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

· Cancer Discov · 2011 · PMID 22586653 · validated civic_curation pubmed

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2016 · PMID 27108243 · validated civic_curation pubmed

A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.

· Am J Cancer Res · 2015 · PMID 26693073 · validated civic_curation pubmed

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

· Cancer Discov · 2016 · PMID 27729313 · validated civic_curation pubmed

GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer.

· Clin Cancer Res · 2005 · PMID 16033819 · validated civic_curation pubmed

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

· Lancet Oncol · 2010 · PMID 20619739 · validated civic_curation pubmed

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Retracted

· N Engl J Med · 2015 · PMID 26287849 · validated civic_curation pubmed

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

· J Clin Oncol · 2018 · PMID 29320312 · validated civic_curation pubmed